Pan-Cancer Analysis of PTBP1 to Identify it as a Prognostic and Immunological Biomarker

Sep 21, 2026

A comprehensive pan-cancer study investigates polypyrimidine tract binding protein 1 (PTBP1) as a prognostic and immunological biomarker. Multi-omics bioinformatics from public resources evaluates PTBP1 expression, genetic alterations, survival associations, immune infiltration, and pathway involvement. PTBP1 is overexpressed across multiple cancer types, with higher mRNA linked to poorer survival. Genetic events include amplification and mutation. PTBP1 modulates tumor immunity by enhancing Treg infiltration and suppressing CD8+ activity, suggesting roles in RNA metabolism, spliceosome, cell cycle, and p53 signaling.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Abstract

Objectives

Methods

Results

Conclusion

Introduction

Pan-Cancer Analysis of PTBP1 to Identify it asa Prognostic and Immunological Biomarker Yan Zhao 1 􀀁, Yanyang Wang2, Qiuqiu Xia 1, Huanhuan He2, Qiming Mao 1, Huaize Dong 1, Lu Zhu 1, Zongyue Hu3, Jiyue Xia 1, Zijing Weng 1, Wenbo Liao 1, and Zhijun Xin 1,4 Cancer Control Volume 31: 1–15 © The Author(s) 2024 Article reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions) [DOI: 10.1177/10732748241302865](DOI: 10.1177/10732748241302865)[ ](DOI: 10.1177/10732748241302865)[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx) Abstract Objectives: Human cancer is considered to be an important cause of death worldwide. Polypyrimidine tract binding protein 1 (PTBP1) is emerging as a powerful pro-oncogenic factor in bladder and liver cancer; however, no pan-cancer analysis is presently available. Our study aimed to explore PTBP1 expression proﬁles, prognostic immunological value, and biological functions across various cancers. Methods: We conducted a comprehensive analysis using multi-omics bioinformatics from public databases, including TIMER, GEPIA2, ProteinAtlas, Kaplan-Meier Plotter, PrognoScan, cBioPortal, STRING, ENCORI, TargetScan, and DAVID. Results: We found that PTBP1 was overexpressed across multiple cancer types. qRT-PCR results demonstrated that the PTBP1 mRNA was signiﬁcantly up-regulated in lung adenocarcinoma (LUAD), colon cancer (COAD), and melanoma (SKCM) cell lines, as well as in melanoma-forming mouse models. Higher PTBP1 mRNA levels were associated with poorer survival probabilities in several cancer types. PTBP1 genetic alterations were related to ampliﬁcation and mutation. PTBP1 signiﬁcantly modulates tumor immunity by enhancing Tregs inﬁltration and reducing CD8+ T cell activity, promoting immune evasion and adversely affecting cancer prognosis. GO and KEGG pathway analyses implied that PTBP1 may participate in RNA metabolism, the spliceosome, the cell cycle, and the p53 signaling pathway in cancer development. Conclusion: Our study is the ﬁrst to demonstrate the oncogenic role of PTBP1 in a pan-cancer context. PTBP1 might serve asa new biomarker for prognostic prediction and immune cell inﬁltration across cancers in the future. Keywords biomarker, cancer, gene expression proﬁles, immune inﬁltration, prognosis, polypyrimidine tract binding protein 1 Received October 31, 2024. Accepted for publication November 8, 2024. 1 Department of Orthopedic Surgery, Afﬁliated Hospital of Zunyi Medical University, Zunyi, China 2Department of Cell Engineering Laboratory, Afﬁliated Hospital of Zunyi Medical University, Zunyi, China 3Department of Pain Rehabilitation, Afﬁliated Sinopharm Gezhouba Central Hospital, Third Clinical Medical College of Three Gorges University, Yichang, China 4Institut Curie, PSL Research University, CNRS UMR3244, Dynamics of Genetic Information, Sorbonne Universit, Paris, France Corresponding Author: Zhijun Xin, Department of Orthopedic Surgery, Afﬁliated Hospital of Zunyi Medical University, 149 Dalian Road, Zunyi 563000, China. Email: [xinzhijun2008@163.com](xinzhijun2008@163.com) Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)). Introduction Human cancer is considered to be one of the most frequent public health problems and an important cause of death worldwide. According to the WHO statistics, cancer has been proven as the leading cause of 10 million deaths in 2020 .1 Throughout the world, cancer incidence and mortali

FAQs

What is the main objective of the study on PTBP1?

To characterize PTBP1 expression patterns across cancers, assess its prognostic value, and determine its immunological relevance and biological functions in a pan-cancer context.

Which analysis sources were used to study PTBP1?

The study used multiple public bioinformatics platforms and datasets, including TIMER, GEPIA2, ProteinAtlas, Kaplan-Meier Plotter, PrognoScan, cBioPortal, STRING, ENCORI, TargetScan, and DAVID.

How does PTBP1 relate to prognosis and tumor immunity?

Higher PTBP1 mRNA levels are associated with worse survival in several cancers. PTBP1 promotes immune evasion by enhancing Tregs infiltration and reducing CD8+ T cell activity.

Sep 21, 2026

Uploaded by Evangeline